USP General Chapter <621> Chromatography: Delay of the Implementation of Two New Requirements
Recommendation
Monday, 29 April 2024 10.00 - 16.00 h
Includes USP Speaker Update on the Analytical Procedure Lifecycle
Register now for ECA's GMP Newsletter
The revised USP General Chapter <621> Chromatography is scheduled to be official on 01 December 2022. The Chemical Analysis Expert Committee has now announced that the implementation of the sections titled "Peak Sensitivity" and "Peak Symmetry" under "System Suitability" will be delayed.
In a Notice of Intent to Revise posted on 26 August 2022, it is stated that, based on the comments received, the committee considered that stakeholders may need additional time to evaluate the impact of these two new requirements.
It is intended that the proposed revision to General Chapter <621> will be published as a Revision Bulletin on 28 October 2022. The Chemical Analysis Expert Committee expects "that during the extended period of implementation stakeholders will evaluate existing compendial procedures and submit comments."
More Information is available on the USP-NF Website.
Related GMP News
24/04/2024
GMP Conferences by Topics
- General Quality Assurance and GMP Compliance Topics
- Hygiene
- General Microbiology Topics
- Regulatory Affairs
- Development
- General Analytics Topics
- Good Distribution Practice
- Sterile Manufacturing
- Computer Validation
- General Qualification/Validation Topics
- General Engineering Topics
- APIs/Excipients
- GMP Basic Training Courses
- Medical Devices and Combination Products
- Packaging and Packaging Material
- Data Integrity
- Qualified Person (QP)
- GMP Auditing
- Documentation
- Cleaning Validation
- General IT Compliance Topics
- Impurities
- OOS / OOE / OOT
- Material Testing
- Validation of Analytical Methods
- Analytical Instrument Qualification
- Stability Testing
- Microbiological Testing
- Technology
- General Manufacturing Topics
- Solid Dosage Forms/Semi-Solid Dosage Forms
- Biotechnology/Blood/ATMP
- Herbal Drug Products/Cannabis/Radiopharmaceuticals
- Others